News Home

Fulcrum Therapeutics Inc (FULC) has fallen -1.71% in a Week, Should You Hold?

Wednesday, November 10, 2021 11:24 AM | InvestorsObserver Analysts
Fulcrum Therapeutics Inc (FULC) has fallen -1.71% in a Week, Should You Hold?

A rating of 90 puts Fulcrum Therapeutics Inc (FULC) near the top of the Biotechnology industry according to InvestorsObserver. Fulcrum Therapeutics Inc's score of 90 means it scores higher than 90% of stocks in the industry. Fulcrum Therapeutics Inc also received an overall rating of 60, putting it above 60% of all stocks. Biotechnology is ranked 87 out of the 148 industries.

Overall Score - 60
FULC has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on FULC!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 60 means the stock is more attractive than 60 percent of stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes


’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Fulcrum Therapeutics Inc Stock Today?

Fulcrum Therapeutics Inc (FULC) stock is up 3.8% while the S&P 500 has fallen -0.06% as of 11:21 AM on Wednesday, Nov 10. FULC has risen $0.76 from the previous closing price of $19.47 on volume of 223,180 shares. Over the past year the S&P 500 is higher by 32.07% while FULC has risen 84.00%. FULC lost -$2.35 per share the over the last 12 months. Click Here to get the full Stock Report for Fulcrum Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App